Latest developments in TAVI

Explore the latest updates to aortic stenosis (AS) management. This includes the new recommendations from the 2021 ESC/EACTS Guidelines and evidence supporting TF-TAVI as the preferred mode of intervention in patients ≥75 years of age**, as well as for additional patient groups >75 years of age¹

**Based on evaluation of clinical, anatomical and procedural factors

What’s new on TAVI.today?

2021 ESC/EACTS VHD Guidelines

All severe aortic stenosis (sAS) patients^* should now be referred to the Heart Team for a treatment evaluation. Read the key guideline updates on the management of AS and how this may impact your daily practice.¹

^*With a treatment indication

TAVI in low-risk patients

Discover the latest data for TAVI in patients with sAS and low surgical risk from the PARTNER 3 Trial. See the survival outcomes and quality of life data for SAPIEN 3 compared with surgery (SAVR).^2,3

Valve-in-valve TAVI

The challenge of long-term management of patients with sAS continues. See how valve-in-valve TAVI can provide an effective solution, and a viable alternative to reoperation in patients with a failed aortic and mitral bioprosthetic valves.⁴

TAVI valve durability

Valve durability is a key consideration for intervention choice. Assess the follow-up data from the PARTNER 3 studies, which establish the durability of the SAPIEN valves used in TAVI, in addition to 10-year real-world data.^5,6

Stay informed with our newsletter

Terms and conditions

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.Read more

Refrences:

1 Vahanian A, et al. Eur Heart J. 2021; ehab395. doi:10.1093/eurheartj/ehab395.
2 Mack MJ, Leon MB, Thourani VH, et al. N Engl J Med 2019;380(18):1695-1705.
3 Baron SJ, Magnuson EA, Lu M, et al. J Am Coll Cardiol 2019;74(23):2833-2842.
4 Shivaraju A, Michel J, Frangieh AH, Ott I, et al. J Am Heart Assoc. 2018;7(14):e007767.
5 Mack MJ, Leon MB, Smith CR, et al.Lancet 2015;385:2477-84.
6 Sathananthan J, et al. Catheter Cardiovasc Interv. 2021;97(3):E431--E437.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

PP--EU-0760 v3.0